EL7.AI
StocksMedium•28 July 2026•
1 min read

Ashland Reports Q3 Sales Growth and Reaffirms Full-Year 2026 Guidance

Key Facts

1Third quarter sales reached $497 million, up 7% compared to the prior-year quarter.
2Adjusted EBITDA fell 4% to $109 million, reflecting lower earnings in Specialty Additives.
3The company reaffirmed its full-year fiscal 2026 sales guidance of $1,835 million to $1,870 million.

Amid shifting dynamics in the specialty chemicals sector, Ashland Inc. reported its fiscal third-quarter 2026 results, with sales reaching $497 million, a 7% increase year-over-year. However, adjusted EBITDA fell by 4% to $109 million, reflecting earnings pressure in specific segments. The company reaffirmed its full-year sales guidance, maintaining a range between $1,835 million and $1,870 million.

The sales growth was primarily supported by higher volumes in the Life Sciences and Personal Care divisions. Conversely, overall profitability was weighed down by lower earnings in the Specialty Additives and Intermediates segments. Per market data, the reaffirmation of guidance suggests a steady outlook despite the current margin pressures observed in the specialty chemical markets.

Shares of ASH stood at $66.38 at the close of July 27, 2026, after trading between a low of $65.63 and a high of $67.03 during the session. With no major upcoming catalysts in the economic calendar directly impacting the stock, investors will likely focus on the company's ability to translate top-line growth into improved EBITDA performance in the final quarter of the fiscal year.